Business Description
Interpace Biosciences Inc
NAICS : 541380
SIC : 8099
ISIN : US46062X3035
Total Employee Number:
102Description
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.45 | |||||
Equity-to-Asset | 0.69 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.27 | |||||
Interest Coverage | 37.11 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -4.55 | |||||
Beneish M-Score | 81.55 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.15 | |||||
9-Day RSI | 37.15 | |||||
14-Day RSI | 39.09 | |||||
3-1 Month Momentum % | -22.95 | |||||
6-1 Month Momentum % | 31.6 | |||||
12-1 Month Momentum % | 70.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.51 | |||||
Quick Ratio | 2.27 | |||||
Cash Ratio | 0.67 | |||||
Days Inventory | 28.82 | |||||
Days Sales Outstanding | 67.55 | |||||
Days Payable | 33.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | 9.9 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.53 | |||||
Operating Margin % | 9.32 | |||||
Net Margin % | 65.25 | |||||
EBITDA Margin % | 11.26 | |||||
FCF Margin % | 13.07 | |||||
OCF Margin % | 13.46 | |||||
ROE % | 272.76 | |||||
ROA % | 111.43 | |||||
ROIC % | 21.67 | |||||
3-Year ROIIC % | 40.51 | |||||
ROC (Joel Greenblatt) % | 50.16 | |||||
ROCE % | 21.43 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 2.06 | |||||
PE Ratio without NRI | 1.98 | |||||
Price-to-Owner-Earnings | 1.68 | |||||
PS Ratio | 0.49 | |||||
PB Ratio | 1.84 | |||||
Price-to-Tangible-Book | 1.84 | |||||
Price-to-Free-Cash-Flow | 5.65 | |||||
Price-to-Operating-Cash-Flow | 5.54 | |||||
EV-to-EBIT | 12.61 | |||||
EV-to-EBITDA | 9.96 | |||||
EV-to-Revenue | 1.12 | |||||
EV-to-Forward-Revenue | 1.28 | |||||
EV-to-FCF | 8.59 | |||||
Price-to-GF-Value | 3.39 | |||||
Price-to-Median-PS-Value | 1.25 | |||||
Price-to-Graham-Number | 0.4 | |||||
Earnings Yield (Greenblatt) % | 7.93 | |||||
FCF Yield % | 11.22 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IDXG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Interpace Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 36.244 | ||
| EPS (TTM) ($) | 0.74 | ||
| Beta | 1.7126 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 0.96 | ||
| Volatility % | 64.77 | ||
| 14-Day RSI | 39.09 | ||
| 14-Day ATR ($) | 0.077447 | ||
| 20-Day SMA ($) | 1.626508 | ||
| 12-1 Month Momentum % | 70.47 | ||
| 52-Week Range ($) | 0.77 - 2.4 | ||
| Shares Outstanding (Mil) | 27.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Interpace Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Interpace Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2020-01-15 | 6.20 (+1.64%) | ||
| 0.1:1 Stock Split | 2016-12-29 | 75.00 (+33.81%) |
Show
Entries
Interpace Biosciences Inc Frequently Asked Questions
What is Interpace Biosciences Inc(IDXG)'s stock price today?
The current price of IDXG is $1.53. The 52 week high of IDXG is $2.40 and 52 week low is $0.77.
When is next earnings date of Interpace Biosciences Inc(IDXG)?
The next earnings date of Interpace Biosciences Inc(IDXG) is .
Does Interpace Biosciences Inc(IDXG) pay dividends? If so, how much?
Interpace Biosciences Inc(IDXG) does not pay dividend.
Guru Commentaries on OTCPK:IDXG
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Interpace Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers